501 related articles for article (PubMed ID: 29656404)
1. Pyoderma gangrenosum in an infant: A case report and review of the literature.
Crouse L; McShane D; Morrell DS; Wu EY
Pediatr Dermatol; 2018 Sep; 35(5):e257-e261. PubMed ID: 29656404
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. [Infliximab for a girl with refractory pyoderma gangrenosum].
Nozawa T; Hara R; Kinoshita J; Sano F; Miyamae T; Imagawa T; Mori M; Hirokado M; Takahashi K; Inayama Y; Yokota S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Dec; 31(6):454-9. PubMed ID: 19122376
[TBL] [Abstract][Full Text] [Related]
4. Treatment of refractory pyoderma gangrenosum with infliximab in a 17-month-old boy.
Bobbitt SA; Klaus EM; Stringer E; Chowdhury D; Finlayson L
Dermatol Online J; 2016 Apr; 22(4):. PubMed ID: 27617462
[TBL] [Abstract][Full Text] [Related]
5. Pyoderma gangrenosum following breast reduction: treatment with topical tacrolimus and steroids.
Doren EL; Aya-ay ML
Aesthet Surg J; 2014 Mar; 34(3):394-9. PubMed ID: 24448967
[TBL] [Abstract][Full Text] [Related]
6. Topical tacrolimus therapy for pyoderma gangrenosum.
Chiba T; Isomura I; Suzuki A; Morita A
J Dermatol; 2005 Mar; 32(3):199-203. PubMed ID: 15863867
[TBL] [Abstract][Full Text] [Related]
7. Refractory pyoderma gangrenosum treated with infliximab in an infant.
Campos-Muñoz L; Conde-Taboada A; Aleo E; Toledano E; López-Bran E
Clin Exp Dermatol; 2014 Apr; 39(3):336-9. PubMed ID: 24635074
[TBL] [Abstract][Full Text] [Related]
8. A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents.
Duchini G; Itin P; Arnold A
Adv Skin Wound Care; 2011 May; 24(5):217-20. PubMed ID: 21505282
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone.
Staub J; Pfannschmidt N; Strohal R; Braun-Falco M; Lohse P; Goerdt S; Leverkus M
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2243-7. PubMed ID: 25352307
[TBL] [Abstract][Full Text] [Related]
10. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
11. A case of vulvar pyoderma gangrenosum associated with collagenous colitis.
Roé E; Dalmau J; García-Navarro X; Corella F; Monfort D; Busquets D; Ribé A; Delgado E; Alomar A
Dermatology; 2006; 213(3):234-5. PubMed ID: 17033174
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Efficacy of Topical Dapsone Treatment for Pyoderma Gangrenosum: A Retrospective Case Series.
Li DG; Din RS; Tsiaras WG; Mostaghimi A
J Cutan Med Surg; 2018; 22(6):650-651. PubMed ID: 30322308
[No Abstract] [Full Text] [Related]
13. Treatment of pyoderma gangrenosum with methotrexate.
Teitel AD
Cutis; 1996 May; 57(5):326-8. PubMed ID: 8726713
[TBL] [Abstract][Full Text] [Related]
14. Infliximab is an appropriate second-line therapy in infants with steroid refractory pyoderma gangrenosum.
Lesmeister LM; Peitz J; von Kleist-Retzow JC; Lee-Kirsch MA; Torrelo A; Tantcheva-Poor I; Broekaert IJ
J Eur Acad Dermatol Venereol; 2022 May; 36(5):e376-e378. PubMed ID: 35037304
[No Abstract] [Full Text] [Related]
15. Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
Hubbard VG; Friedmann AC; Goldsmith P
Br J Dermatol; 2005 May; 152(5):1059-61. PubMed ID: 15888172
[TBL] [Abstract][Full Text] [Related]
16. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis.
Baumgart DC; Wiedenmann B; Dignass AU
Inflamm Bowel Dis; 2004 Jul; 10(4):421-4. PubMed ID: 15475751
[TBL] [Abstract][Full Text] [Related]
17. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
[TBL] [Abstract][Full Text] [Related]
18. A Case Series of 4 Patients With Peristomal Pyoderma Gangrenosum: Review of Risk Factors and Treatment Response.
Turrión-Merino L; Hermosa-Zarza E; Miguel L; Muñoz-Zato E
Actas Dermosifiliogr; 2016 Apr; 107(3):e13-7. PubMed ID: 26626501
[TBL] [Abstract][Full Text] [Related]
19. [Pyoderma gangrenosum: successful topical therapy with tacrolimus (FK506)].
Petering H; Kiehl P; Breuer C; Kapp A; Werfel T
Hautarzt; 2001 Jan; 52(1):47-50. PubMed ID: 11220239
[TBL] [Abstract][Full Text] [Related]
20. Systemic absorption of topical tacrolimus in Pyoderma gangrenosum.
Pitarch G; Torrijos A; Mahiques L; Sánchez-Carazo JL; Fortea JM
Acta Derm Venereol; 2006; 86(1):64-5. PubMed ID: 16585995
[No Abstract] [Full Text] [Related]
[Next] [New Search]
